All In Biotech

Drug Trial Radar · NCT06470763

A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)

A First-in-human, Open-label, Multicenter Phase I/II Study to Evaluate the Safety and Anti-tumor Activity of ANV600 as Single Agent and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)

Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

63

Actual

Start

Jul 1, 2024

Primary completion

Jun 22, 2026

Study completion Jun 22, 2026

Sponsor

Lead sponsor
Anaveon AGIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jun 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of study ANV600-001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and antitumor activity of ANV600 administered as a single agent or in combination with pembrolizumab in adult participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • ANV600Drug

    ANV600 administered by intravenous (IV) infusion

  • ANV600 + pembrolizumab (KEYTRUDA®)Drug

    ANV600 administered by intravenous (IV) infusion pembrolizumab (KEYTRUDA®) administered by intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I dose escalation: Incidence of Dose Limiting Toxicities (DLT) with ANV600 single agent and in combination with pembrolizumab combination with pembrolizumabTime frame: Day 1 up to 24 months
  2. Phase I dose escalation: Frequency and severity of treatment-emergent adverse events (TEAEs) with ANV600 and in combination with pembrolizumabTime frame: Day 1 up to 24 months
  3. Phase II: Objective Response Rate (ORR) using RECIST v1.1Time frame: Day 1 up to 24 months
  4. Phase II: Duration of Response (DOR) using RECIST v1.1Time frame: Day 1 up to 24 months

Locations

18 sites in 7 countries. Site status is shown where the registry gives one.

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Institut Bergonie

    Bordeaux, France

  • CEPCM - AP-HM Hopital de la Timone

    Marseille, France

  • Oncopole Claudius Regaud, Toulouse

    Toulouse, France

  • Institut Gustave Roussy

    Villejuif, France

  • Charite Universitaetsmedizin Berlin

    Berlin, Germany

  • Krankenhaus Nordwest - Institut für Klinisch-Onkologische Forschung (IKF)

    Frankfurt, Germany

  • Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz

    Mainz, Germany

  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)

    Amsterdam, Netherlands

  • Vall d'Hebron Institute of Oncology (VHIO)

    Barcelona, Spain

  • START Madrid CIOCC

    Madrid, Spain

  • Clinica Universidad de Navarra - Pamplona

    Pamplona, Spain

  • INCLIVA Foundation

    Valencia, Spain

  • Ente Ospedaliero Cantonale - Istituto Oncologico della Svizzera Italiana

    Bellinzona, Switzerland

  • Cantonal Hospital St Gallen

    Sankt Gallen, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.